• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Molecular MRD testing in patients with acute myeloid leukemia.

作者信息

Blackmon Amanda L, Grunwald Michael R

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, USA.

出版信息

Bone Marrow Transplant. 2025 Feb;60(2):119-121. doi: 10.1038/s41409-024-02493-y. Epub 2025 Jan 11.

DOI:10.1038/s41409-024-02493-y
PMID:39799198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11810761/
Abstract
摘要

相似文献

1
Editorial: Molecular MRD testing in patients with acute myeloid leukemia.社论：急性髓系白血病患者的分子微小残留病检测
Bone Marrow Transplant. 2025 Feb;60(2):119-121. doi: 10.1038/s41409-024-02493-y. Epub 2025 Jan 11.
2
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.检测后清除？急性髓系白血病中可测量残留疾病检测的现状和未来机遇。
Acta Haematol. 2024;147(2):133-146. doi: 10.1159/000535463. Epub 2023 Nov 30.
3
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.急性髓系白血病的最佳可测量残留病检测
Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18.
4
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.多基因可测量残留病评估改善自体造血细胞移植中急性髓系白血病的复发风险分层
Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17.
5
Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.移植前分子可测量残留病可独立预测成人赖氨酸甲基转移酶2a重排急性髓系白血病的生存率和复发风险。
Cancer. 2025 Jan 15;131(2):e35717. doi: 10.1002/cncr.35717.
6
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.急性髓系白血病微小残留病检测面临的挑战及克服这些挑战的有前途的策略。
Expert Rev Hematol. 2023 Jul-Dec;16(12):981-990. doi: 10.1080/17474086.2023.2285985. Epub 2023 Dec 18.
7
Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.游离 DNA 5-羟甲基胞嘧啶对急性髓系白血病微小残留病的评估具有高度敏感性。
Clin Epigenetics. 2023 Aug 24;15(1):134. doi: 10.1186/s13148-023-01547-0.
8
Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.干扰素-α 对异基因造血干细胞移植后 t(8;21) 急性髓系白血病患者微小残留病的治疗有效：一项前瞻性登记研究的结果。
Oncologist. 2018 Nov;23(11):1349-1357. doi: 10.1634/theoncologist.2017-0692. Epub 2018 Aug 3.
9
Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.诱导后两个时间点多参数流式细胞术微小残留病对儿童急性髓系白血病预后的意义。
BMC Cancer. 2024 Jan 9;24(1):46. doi: 10.1186/s12885-023-11784-4.
10
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.与匹配的相关或无关供体移植相比，高危急性髓系白血病患者在脐血移植前采用非清髓性预处理方案的预后较差。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14.

本文引用的文献

1
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
2
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
3
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
检测后清除？急性髓系白血病中可测量残留疾病检测的现状和未来机遇。
Acta Haematol. 2024;147(2):133-146. doi: 10.1159/000535463. Epub 2023 Nov 30.
4
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.DNA 测序检测造血细胞移植前急性髓系白血病成人患者的残留疾病。
JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.
5
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.急性髓系白血病免疫表型可测量残留病灶清除的分子预测因子。
Am J Hematol. 2023 Jan;98(1):79-89. doi: 10.1002/ajh.26757. Epub 2022 Oct 31.
6
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
7
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.2021 年急性髓系白血病微小残留病更新：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626.
8
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.在减低强度或非清髓性异基因干细胞移植前，急性髓系白血病患者缓解和可测量残留病状态的预后相关性。
Blood Cancer J. 2021 Apr 29;11(4):80. doi: 10.1038/s41408-021-00471-x.
9
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Venetoclax 治疗复发/难治性 AML 的反应和生存的临床和分子预测因子。
Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734.
10
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.有残留疾病基因组证据的急性髓细胞性白血病异体移植的条件强度的影响。
J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20.